Sandbox/Alejandro: Difference between revisions

Jump to navigation Jump to search
(Created page with "==Empiric Therapy<SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from Clinical Practice Guidelines CID 2011<ref name="Mathews-2010">{{Cite journal | last1 = Mathews | first1 = CJ....")
 
No edit summary
Line 46: Line 46:
</div>
</div>


<div class="mw-customtoggle-table10" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table08" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
Line 52: Line 52:
</div>
</div>


<div class="mw-customtoggle-table11" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table09" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children age >28 days'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children age >28 days'''
Line 58: Line 58:
</div>
</div>


 
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
'''Complicated Cellulitis'''
'''Complicated Cellulitis†'''
</font>
</font>
</div>
</div>


<div class="mw-customtoggle-table12" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table10" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
Line 71: Line 70:
</div>
</div>


<div class="mw-customtoggle-table13" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table11" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children age >28 days'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children age >28 days'''
Line 140: Line 139:
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table10" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table08" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
Line 155: Line 154:
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table10" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table08" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
Line 170: Line 169:
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table11" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table09" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
Line 185: Line 184:
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table11" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table09" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
Line 200: Line 199:
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table12" style="background: #FFFFFF;"
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table10" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
Line 207: Line 207:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Vancomycin]]  40 mg/kg/day IV in 4 divided doses'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Vancomycin]]  15-20 mg/kg IV q8-12h'''''<BR> OR <BR>▸ '''''[[Linezolid]] 600 mg IV q12h'''''<BR> OR <BR>  ▸ '''''[[Daptomycin]] 4mg/kg IV q24h''''' <BR> OR <BR>  ▸ '''''[[Telavancin]] 10mg/kg IV q24h'''''  
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Linezolid]] 10 mg/kg IV q12h'''''<BR> OR <BR> ▸ '''''[[Clindamycin]] 25–40 mg/kg/day IV in 3 divided dose'''''<BR> OR <BR>  ▸ '''''[[Trimethoprim-sulfamethoxazole]] 8–12 mg/kg/day (based on the trimethoprim component) IV in 4 divided doses'''''  
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |   ▸ '''''[[Clindamycin]] 600 mg IV q8h'''''
|-
|-
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table12" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table10" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
Line 222: Line 222:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Linezolid]] 10 mg/kg orally q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Linezolid]] 600 mg PO q12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |  ▸ '''''[[Clindamycin]] 10-20 mg/kg per day orally divided in 3 doses'''''<BR> OR <BR> ▸ '''''[[Trimethoprim-sulfamethoxazole]]  8-12 mg trimethoprim component/kg per day orally divided in 2 doses'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |  ▸ '''''[[Clindamycin]]'' 600 mg PO q8h'''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL> <sup></sup> Complicated cellulitis refers to a deeper soft-tissue infections and the association with necrotizing fasciitis, septic arthritis, or osteomyelitis</SMALL>
|-
|-
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table13" style="background: #FFFFFF;"
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table11" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
Line 237: Line 240:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Vancomycin]]  15-20 mg/kg IV q8-12h'''''<BR> OR <BR>▸ '''''[[Linezolid]] 600 mg IV q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Vancomycin]]  15 mg/kg IV q6h'''''<BR> OR <BR>▸ '''''[[Linezolid]] 10 mg/kg IV q8h (max: 600mg/dose)'''''
<BR> OR <BR>  ▸ '''''[[Daptomycin]] 4mg/kg IV q24h''''' <BR> OR <BR>  ▸ '''''[[Telavancin]] 10mg/kg IV q24h'''''  
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |  ▸ '''''[[Clindamycin]] 600 mg IV q8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |  ▸ '''''[[Clindamycin]] 10-13 mg/kg IV q6-8h  (max:40 mg/kg/day)'''''
|-
|-
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table13" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table11" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
Line 253: Line 255:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Linezolid]] 600 mg PO q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Linezolid]] 10 mg/kg PO q8h (max: 600mg/dose)''''' <br> OR <br> ▸ '''''[[Clindamycin]] 10-13 mg/kg PO q6-8h  (max:40 mg/kg/day)'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |  ▸ '''''[[Clindamycin]]'' 600 mg PO q8h'''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL> <sup>†</sup> Complicated cellulitis refers to a deeper soft-tissue infections and the association with necrotizing fasciitis, septic arthritis, or osteomyelitis<SMALL>
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL> <sup>†</sup> Complicated cellulitis refers to a deeper soft-tissue infections and the association with necrotizing fasciitis, septic arthritis, or osteomyelitis</SMALL>
|-
|-
|}
|}

Revision as of 19:06, 23 May 2014

Empiric TherapyAdapted from Clinical Practice Guidelines CID 2011[1] and Guidelines for Skin and Soft-Tissue Infections CID 2005[2]

▸ Click on the following categories to expand treatment regimens.

Cellulitis

Non-purulent Cellulitis

  ▸  Adults

  ▸  Children age >28 days

Purulent Cellulitis

  ▸  Adults

  ▸  Children age >28 days

Complicated Cellulitis†

  ▸  Adults

  ▸  Children age >28 days


Parental Regimen
Preferred Regimen
Oxacillin 2g IV q4h
OR
Nafcillin 2g IV q4h
Alternative Regimen (penicillin-allergic patients)
Cefazolin 1-2 g IV q8h (without immediate hypersensitivity reactions)
OR
Clindamycin 600 mg IV q8h (with immediate hypersensitivity reactions)
Oral Regimen
Preferred Regimen
Dicloxacillin 500 mg orally q6h
Alternative Regimen (penicillin-allergic patients)
Cephalexin 500 mg orally q6h (without immediate hypersensitivity reactions)
OR
Doxycycline 100 mg orally q12h
OR
Minocycline 100 mg orally q12h
OR
Trimethoprim-sulfamethoxazole 1 or 2 double-strength tablets orally q12h
OR
Clindamycin 300–450 mg orally q8h
Parental Regimen
Preferred Regimen
Oxacillin 100-150 mg/kg per day IV in 4 doses
OR
Nafcillin 100-150 mg/kg per day IV in 4 doses
Alternative Regimen (penicillin-allergic patients)
Cefazolin 50 mg/kg per day IV in 3 doses (without immediate hypersensitivity reactions)
OR
Clindamycin 25-40 mg/kg per day IV in 3 doses(with immediate hypersensitivity reactions)
OR
Trimethoprim-sulfamethoxazole 8–12 mg/kg IV in 4 doses
Oral Regimen
Preferred Regimen
Dicloxacillin 25 mg/kg per day orally in 4 doses
Alternative Regimen (penicillin-allergic patients)
Cephalexin 25 mg/kg per day orally in 4 doses(without immediate hypersensitivity reactions)
OR
Clindamycin 10-20 mg/kg per day orally in 4 doses
OR
Trimethoprim-sulfamethoxazole 8–12 mg/kg orally in 2 doses
Parental Regimen
Preferred Regimen
Vancomycin 30 mg/kg/dose IV q12h
Alternative Regimen
Linezolid 600 mg IV q12h
OR
Clindamycin 600 mg IV q8h
OR
Daptomycin 4 mg/kg IV q24h
Oral Regimen
Preferred Regimen
Linezolid 600 mg orally q12h
Alternative Regimen
Clindamycin 300 to 450 mg q8h
OR
Linezolid 600 mg orally q12h
OR
Minocycline 100 mg orally q12h
OR
Doxycycline 100 mg orally q12h
OR
Trimethoprim-sulfamethoxazole 1 or 2 double-strength tablets orally q12h
Parental Regimen
Preferred Regimen
Vancomycin 40 mg/kg/day IV in 4 divided doses
Alternative Regimen
Linezolid 10 mg/kg IV q12h
OR
Clindamycin 25–40 mg/kg/day IV in 3 divided dose
OR
Trimethoprim-sulfamethoxazole 8–12 mg/kg/day (based on the trimethoprim component) IV in 4 divided doses
Oral Regimen
Preferred Regimen
Linezolid 10 mg/kg orally q12h
Alternative Regimen
Clindamycin 10-20 mg/kg per day orally divided in 3 doses
OR
Trimethoprim-sulfamethoxazole 8-12 mg trimethoprim component/kg per day orally divided in 2 doses
Parental Regimen
Preferred Regimen
Vancomycin 15-20 mg/kg IV q8-12h
OR
Linezolid 600 mg IV q12h
OR
Daptomycin 4mg/kg IV q24h
OR
Telavancin 10mg/kg IV q24h
Alternative Regimen
Clindamycin 600 mg IV q8h
Oral Regimen
Preferred Regimen
Linezolid 600 mg PO q12h
Alternative Regimen
Clindamycin 600 mg PO q8h
Complicated cellulitis refers to a deeper soft-tissue infections and the association with necrotizing fasciitis, septic arthritis, or osteomyelitis
Parental Regimen
Preferred Regimen
Vancomycin 15 mg/kg IV q6h
OR
Linezolid 10 mg/kg IV q8h (max: 600mg/dose)
Alternative Regimen
Clindamycin 10-13 mg/kg IV q6-8h (max:40 mg/kg/day)
Oral Regimen
Preferred Regimen
Linezolid 10 mg/kg PO q8h (max: 600mg/dose)
OR
Clindamycin 10-13 mg/kg PO q6-8h (max:40 mg/kg/day)
Complicated cellulitis refers to a deeper soft-tissue infections and the association with necrotizing fasciitis, septic arthritis, or osteomyelitis

Note:

  • Treatment of cellulitis in neonates usually requires hospitalization and parenteral therapy. Oral therapy is given for completion of the treatment when the patogen is unknown.
  • Optimal dose should be based on determination of serum concentrations.
  • The above antibiotic regimen is NOT for initial empirical treatment of infections involving the face.
  • Dose alteration for renal insufficiency may be needed in case of cephalosporins.
  • Clindamycin is an alternate therapy for patients at risk of severe hypersensitivity reaction to penicillins and cephalosporins.
  • Doxycycline is NOT recommended for children <8 years of age.
  • Studies have shown an increase in treatment failure with TMP-SMX compared to other agents for cellulitis in children, reflecting TMP-SMX less action against Group A streptococcus.[3]
  1. Mathews, CJ.; Weston, VC.; Jones, A.; Field, M.; Coakley, G. (2010). "Bacterial septic arthritis in adults". Lancet. 375 (9717): 846–55. doi:10.1016/S0140-6736(09)61595-6. PMID 20206778. Unknown parameter |month= ignored (help)
  2. Dennis L. Stevens, Alan L. Bisno, Henry F. Chambers, E. Dale Everett, Patchen Dellinger, Ellie J. C. Goldstein, Sherwood L. Gorbach, Jan V. Hirschmann, Edward L. Kaplan, Jose G. Montoya & James C. Wade (2005). "Practice guidelines for the diagnosis and management of skin and soft-tissue infections". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 41 (10): 1373–1406. doi:10.1086/497143. PMID 16231249. Unknown parameter |month= ignored (help)
  3. Elliott DJ, Zaoutis TE, Troxel AB, Loh A, Keren R (2009). "Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus". Pediatrics. 123 (6): e959–66. doi:10.1542/peds.2008-2428. PMID 19470525.